SAN DIEGO, CA (April 09, 2015) – PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, announced today the Company will present at the 2nd Growth Capital Expo being held on April 12-14, 2015 at Caesars Palace in Las Vegas, NV.
Hank R. Lambert, CEO, will present on Monday, April 13, 2015 at 10:30am Pacific Time. Lambert will review progress of the commercialization of SDC as a food safety solution.
The presentation will be webcast live with slides (and available for replay) and can be accessed on the Company's website, http://www.purebio.com/about/investor_relations.
If you would like to attend the Company’s presentation at the Conference, please click the following link: Register
About Growth Capital Expo
The Growth Capital Expo brings together the best ideas, the most promising companies and the top deal makers in emerging growth finance for three days of education and networking in the nation’s premier destination for meetings and entertainment. Join the top growth company executives, investors and finance specialists focused on the pre-IPO and public microcap market for an unparalleled experience in education, networking and deal making.
About PURE Bioscience, Inc.
PURE Bioscience, Inc. is focused on developing and commercializing our proprietary antimicrobial products primarily in the food safety arena -- providing solutions to the health and environmental challenges of pathogen and hygienic control. Our technology platform is based on patented stabilized ionic silver, and our initial products contain silver dihydrogen citrate, or SDC. SDC is a broad-spectrum, non-toxic antimicrobial agent, which offers 24-hour residual protection and formulates well with other compounds. As a platform technology, SDC is distinguished from existing products in the marketplace because of its superior efficacy, reduced toxicity and the inability of bacteria to form a resistance to it. PURE is headquartered in El Cajon, California (San Diego metropolitan area). Additional information on PURE is available at www.purebio.com.
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause our actual results to differ materially from the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, the Company’s cash position and liquidity requirements; the Company’s failure to implement or otherwise achieve the benefits of its proposed business initiatives and plans; acceptance of the Company's current and future products and services in the marketplace, including acceptance of the Company’s PURE Hard Surface disinfectant by SUBWAY® franchisees and the ability to convert successful evaluations into customer orders; the ability of the Company to develop effective new products and receive regulatory approvals of such products, including the required data and regulatory approvals to support the use of its SDC-based technology as a direct food contact processing aid; competitive factors; dependence upon third-party vendors, including to manufacture its products; and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission, including our quarterly report on Form 10-Q filed on March 4, 2015. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.
Peter C. Wulff, CFO & COO
PURE Bioscience, Inc.